Source 1review2015International Journal of Ophthalmology & Eye Science
Toolkit/small interfering RNA
small interfering RNA
Also known as: Short-interfering RNAs, siRNA, siRNAs, small interfering RNAs
Taxonomy: Mechanism Branch / Component. Workflows sit above the mechanism and technique branches rather than replacing them.
Summary
Small interfering RNA (siRNA) is a short RNA modality used to transiently downregulate expression of a target gene by exploiting the RNA interference pathway. In the supplied evidence, siRNA is described as a gene-therapy approach for altering gene expression rather than a genome-editing reagent.
Usefulness & Problems
Why this is useful
siRNA is useful for transient suppression of target gene expression without changing genomic DNA. The evidence supports its use as one of several molecular medicine approaches used to alter gene expression.
Problem solved
siRNA helps solve the problem of reducing expression of a chosen gene when transient knockdown is desired. The supplied evidence specifically frames this as modulation of gene expression rather than editing.
Problem links
addressing undruggable targets via RNA-based treatment
LiteratureIt enables targeted gene knockdown and is presented as a potential treatment modality for otherwise undruggable targets.
Source:
It enables targeted gene knockdown and is presented as a potential treatment modality for otherwise undruggable targets.
provides a gene-therapy route for manipulating pain-associated targets
LiteratureThey offer a way to manipulate pain-related targets through gene-based intervention.
Source:
They offer a way to manipulate pain-related targets through gene-based intervention.
providing a modality to suppress NF-κβ activity
LiteratureIt is proposed as a way to reduce excessive NF-κβ signaling associated with chronic inflammation in IBD.
Source:
It is proposed as a way to reduce excessive NF-κβ signaling associated with chronic inflammation in IBD.
providing an RNA-based therapeutic modality for disease treatment
LiteraturesiRNA supports therapeutic intervention at the RNA level, contributing to disease-directed gene silencing approaches.
Source:
siRNA supports therapeutic intervention at the RNA level, contributing to disease-directed gene silencing approaches.
silencing target gene expression
LiteratureIt enables targeted gene knockdown and is presented as a potential treatment modality for otherwise undruggable targets.
Source:
It enables targeted gene knockdown and is presented as a potential treatment modality for otherwise undruggable targets.
Published Workflows
Objective: Guide the design and testing of siRNA sequences from initial in silico design through research or therapeutic application to achieve effective gene knockdown in vitro and in vivo.
Why it works: The review presents a sequence of design and testing considerations in which early sequence design aims to improve on-target knockdown and reduce off-target effects, followed by in vitro assessment and controls, then additional in vivo-focused delivery and safety considerations.
target mRNA degradationguide or antisense strand incorporation into RISCreduced off-target RNAichemical modification effects on RISC interactionin silico designin vitro efficacy assessmentnonsilencing control designdelivery method selectionchemical modification of siRNA
Stages
- 1.Initial in silico siRNA design(in_silico_filter)
The abstract states that siRNA sequences must be precisely designed and that the guide starts from initial in silico design.
Selection: Design siRNA sequences for effective gene knockdown while minimizing off-target effects.
- 2.In vitro efficacy assessment and control design(functional_characterization)
The abstract explicitly states that the review discusses assessment of siRNA efficacy in vitro and the design of appropriate nonsilencing controls.
Selection: Assess siRNA efficacy in vitro and design appropriate nonsilencing controls.
- 3.In vivo application planning(secondary_characterization)
The abstract identifies these as challenges of in vivo applications and highlights strategies to overcome them.
Selection: Address delivery methods, biodistribution, and immunotoxicity prevention for in vivo siRNA use.
- 4.Chemical modification optimization(secondary_characterization)
The abstract explicitly discusses nucleotide chemical modifications and their effects on siRNA properties relevant to function.
Selection: Evaluate ribose sugar and phosphodiester bond modifications for their effects on stability, activity, and RISC interaction.
Steps
- 1.Design siRNA sequences in silicoengineered RNA sequence being designed
Generate siRNA candidates expected to produce effective gene knockdown.
The abstract states that the process starts from initial in silico design before later testing and application.
- 2.Prioritize designs that reduce off-target RNAi and favor intended guide-strand incorporation into RISCsiRNA candidate under prioritization
Improve targeted knockdown by reducing off-target effects and promoting correct strand loading.
The abstract emphasizes these design approaches as part of achieving optimal efficacy before experimental assessment.
- 3.Assess siRNA efficacy in vitrosiRNA candidate being tested
Measure whether designed siRNA sequences achieve effective knockdown under in vitro conditions.
The abstract explicitly discusses in vitro efficacy assessment after design-focused considerations and before in vivo application issues.
- 4.Design appropriate nonsilencing controls
Support rigorous interpretation of siRNA efficacy experiments.
The abstract pairs in vitro efficacy assessment with design of appropriate nonsilencing controls as part of rigorous testing.
- 5.Address delivery, biodistribution, and immunotoxicity for in vivo applicationsiRNA therapeutic candidate under translational planning
Prepare siRNA candidates for in vivo use by addressing major translational barriers.
The abstract presents these as challenges of in vivo applications that are considered after design and in vitro assessment.
- 6.Evaluate nucleotide chemical modifications affecting stability, activity, and RISC interactionsiRNA and its chemical modification strategy
Optimize functional properties of siRNA through ribose sugar and phosphodiester bond modifications.
The abstract explicitly highlights chemical modification as a design consideration tied to stability, activity, and RISC interaction in the overall guide.
Taxonomy & Function
Primary hierarchy
Mechanism Branch
Component: A low-level RNA part used inside a larger architecture that realizes a mechanism.
Techniques
No technique tags yet.
Target processes
editingrecombinationInput: Light
Implementation Constraints
cofactor dependency: cofactor requirement unknownencoding mode: genetically encodedimplementation constraint: context specific validationimplementation constraint: spectral hardware requirementoperating role: sensor
The supplied evidence identifies siRNA as a short-interfering RNA approach that functions through the RNA interference pathway. No construct design rules, chemical modifications, delivery systems, cofactors, or expression platforms are described in the provided sources.
The evidence only supports transient downregulation and does not describe permanent genome modification. No specific data are provided on delivery, potency, specificity, duration, organismal validation, or comparative performance.
Validation
Cell-freeBacteriaMammalianMouseHumanTherapeuticIndep. Replication
Supporting Sources
Source 2review2024Cell Reports Medicine
Source 3primary paper2026MED
Source 4review2018Frontiers in Pediatrics
Source 5review2018Frontiers in Plant Science
Ranked Claims
RNA-based strategies are applied to gene silencing, editing, protein replacement, immune activation, and targeted drug delivery.
ASOs and siRNAs receive special emphasis for neurological, metabolic, and infectious diseases.
RNA-targeted therapy is shifting molecular medicine from a protein-centric view toward an RNA-regulatory network paradigm.
Diverse RNA therapeutics include ASOs, siRNA, miRNA modulators, mRNA therapeutics, aptamers, shRNA, and CRISPR/Cas-guided single-guide RNAs.
Chemical modification, nanotechnology, and artificial intelligence-assisted design are enhancing the specificity, stability, and safety of RNA therapeutics.
Common challenges for RNA therapeutics include in vivo stability, delivery efficiency, and immune activation.
Gene-therapy modalities including ASOs, RNAi, CRISPR, and virus-based delivery systems have played crucial roles in discovering and validating new pain targets.
The review covers ASOs, siRNAs, optogenetics, chemogenetics, CRISPR, and their delivery methods targeting primary sensory neurons and non-neuronal cells including glia and chondrocytes.
Although gene therapy-based clinical trials have increased, trials focused on pain as the primary outcome remain uncommon.
Available reports indicate that lncRNAs have roles in photomorphogenesis, cotyledon greening, and photoperiod-regulated flowering.
In the lncRNA world, few reports are available, but they already indicate a role in the regulation of photomorphogenesis, cotyledon greening, and photoperiod-regulated flowering.
miRNAs can mediate several light-regulated processes.
In addition, miRNAs can mediate several light-regulated processes.
miRNAs can mediate several light-regulated processes.
In addition, miRNAs can mediate several light-regulated processes.
miRNAs can mediate several light-regulated processes.
In addition, miRNAs can mediate several light-regulated processes.
miRNAs can mediate several light-regulated processes.
In addition, miRNAs can mediate several light-regulated processes.
miRNAs can mediate several light-regulated processes.
In addition, miRNAs can mediate several light-regulated processes.
miRNAs can mediate several light-regulated processes.
In addition, miRNAs can mediate several light-regulated processes.
miRNAs can mediate several light-regulated processes.
In addition, miRNAs can mediate several light-regulated processes.
Light can affect MIRNA gene transcription, miRNA biogenesis, and RISC activity, thereby influencing miRNA accumulation and biological function.
Light can affect MIRNA gene transcription, miRNA biogenesis, and RNA-induced silencing complex (RISC) activity, thus controlling not only miRNA accumulation but also their biological function.
Light can affect MIRNA gene transcription, miRNA biogenesis, and RISC activity, thereby influencing miRNA accumulation and biological function.
Light can affect MIRNA gene transcription, miRNA biogenesis, and RNA-induced silencing complex (RISC) activity, thus controlling not only miRNA accumulation but also their biological function.
Light can affect MIRNA gene transcription, miRNA biogenesis, and RISC activity, thereby influencing miRNA accumulation and biological function.
Light can affect MIRNA gene transcription, miRNA biogenesis, and RNA-induced silencing complex (RISC) activity, thus controlling not only miRNA accumulation but also their biological function.
Light can affect MIRNA gene transcription, miRNA biogenesis, and RISC activity, thereby influencing miRNA accumulation and biological function.
Light can affect MIRNA gene transcription, miRNA biogenesis, and RNA-induced silencing complex (RISC) activity, thus controlling not only miRNA accumulation but also their biological function.
Light can affect MIRNA gene transcription, miRNA biogenesis, and RISC activity, thereby influencing miRNA accumulation and biological function.
Light can affect MIRNA gene transcription, miRNA biogenesis, and RNA-induced silencing complex (RISC) activity, thus controlling not only miRNA accumulation but also their biological function.
Light can affect MIRNA gene transcription, miRNA biogenesis, and RISC activity, thereby influencing miRNA accumulation and biological function.
Light can affect MIRNA gene transcription, miRNA biogenesis, and RNA-induced silencing complex (RISC) activity, thus controlling not only miRNA accumulation but also their biological function.
Light can affect MIRNA gene transcription, miRNA biogenesis, and RISC activity, thereby influencing miRNA accumulation and biological function.
Light can affect MIRNA gene transcription, miRNA biogenesis, and RNA-induced silencing complex (RISC) activity, thus controlling not only miRNA accumulation but also their biological function.
The review states that non-protein-coding RNAs are biologically relevant regulators of critical plant processes.
The biological relevance of non-protein coding RNAs in the regulation of critical plant processes has been firmly established in recent years.
The review states that non-protein-coding RNAs are biologically relevant regulators of critical plant processes.
The biological relevance of non-protein coding RNAs in the regulation of critical plant processes has been firmly established in recent years.
The review states that non-protein-coding RNAs are biologically relevant regulators of critical plant processes.
The biological relevance of non-protein coding RNAs in the regulation of critical plant processes has been firmly established in recent years.
The review states that non-protein-coding RNAs are biologically relevant regulators of critical plant processes.
The biological relevance of non-protein coding RNAs in the regulation of critical plant processes has been firmly established in recent years.
The review states that non-protein-coding RNAs are biologically relevant regulators of critical plant processes.
The biological relevance of non-protein coding RNAs in the regulation of critical plant processes has been firmly established in recent years.
The review states that non-protein-coding RNAs are biologically relevant regulators of critical plant processes.
The biological relevance of non-protein coding RNAs in the regulation of critical plant processes has been firmly established in recent years.
The review states that non-protein-coding RNAs are biologically relevant regulators of critical plant processes.
The biological relevance of non-protein coding RNAs in the regulation of critical plant processes has been firmly established in recent years.
Recent next-generation sequencing techniques expanded the recognized landscape of non-coding RNAs to include lncRNAs.
recent next-generation sequencing techniques have widened our view of the non-coding RNA world, which now includes long non-coding RNAs (lncRNAs)
Suppression of NF-κβ can be achieved through modalities including ASOs, siRNA, factors regulating NF-κβ, and microbes.
CRISPR/Cas9 is described as a genome editing system that interrupts gene expression through cleavage of target DNA.
The bacterial Type II Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 genome editing system is the latest method of interrupting gene expression through cleavage of target DNA.
siRNAs are described as a method for transient downregulation of target gene expression through the RNA interference pathway.
Short-interfering RNAs (siRNAs) are one method of transiently down regulating the expression of any target gene through the exploitation of the RNA interference pathway
siRNAs are described as a method for transient downregulation of target gene expression through the RNA interference pathway.
Short-interfering RNAs (siRNAs) are one method of transiently down regulating the expression of any target gene through the exploitation of the RNA interference pathway
siRNAs are described as a method for transient downregulation of target gene expression through the RNA interference pathway.
Short-interfering RNAs (siRNAs) are one method of transiently down regulating the expression of any target gene through the exploitation of the RNA interference pathway
siRNAs are described as a method for transient downregulation of target gene expression through the RNA interference pathway.
Short-interfering RNAs (siRNAs) are one method of transiently down regulating the expression of any target gene through the exploitation of the RNA interference pathway
siRNAs are described as a method for transient downregulation of target gene expression through the RNA interference pathway.
Short-interfering RNAs (siRNAs) are one method of transiently down regulating the expression of any target gene through the exploitation of the RNA interference pathway
siRNAs are described as a method for transient downregulation of target gene expression through the RNA interference pathway.
Short-interfering RNAs (siRNAs) are one method of transiently down regulating the expression of any target gene through the exploitation of the RNA interference pathway
siRNAs are described as a method for transient downregulation of target gene expression through the RNA interference pathway.
Short-interfering RNAs (siRNAs) are one method of transiently down regulating the expression of any target gene through the exploitation of the RNA interference pathway
TALENs are described as artificial systems that can be designed and constructed relatively quickly to bind practically anywhere in the genome and cleave double-stranded DNA, thereby interrupting expression of a target gene.
Transcription activator-like effector nucleases (TALENs) are artificial systems that can be designed and constructed relatively quickly to bind practically anywhere in the genome and cleave double stranded DNA, thus interrupting the expression of any given target gene
TALENs are described as artificial systems that can be designed and constructed relatively quickly to bind practically anywhere in the genome and cleave double-stranded DNA, thereby interrupting expression of a target gene.
Transcription activator-like effector nucleases (TALENs) are artificial systems that can be designed and constructed relatively quickly to bind practically anywhere in the genome and cleave double stranded DNA, thus interrupting the expression of any given target gene
TALENs are described as artificial systems that can be designed and constructed relatively quickly to bind practically anywhere in the genome and cleave double-stranded DNA, thereby interrupting expression of a target gene.
Transcription activator-like effector nucleases (TALENs) are artificial systems that can be designed and constructed relatively quickly to bind practically anywhere in the genome and cleave double stranded DNA, thus interrupting the expression of any given target gene
TALENs are described as artificial systems that can be designed and constructed relatively quickly to bind practically anywhere in the genome and cleave double-stranded DNA, thereby interrupting expression of a target gene.
Transcription activator-like effector nucleases (TALENs) are artificial systems that can be designed and constructed relatively quickly to bind practically anywhere in the genome and cleave double stranded DNA, thus interrupting the expression of any given target gene
TALENs are described as artificial systems that can be designed and constructed relatively quickly to bind practically anywhere in the genome and cleave double-stranded DNA, thereby interrupting expression of a target gene.
Transcription activator-like effector nucleases (TALENs) are artificial systems that can be designed and constructed relatively quickly to bind practically anywhere in the genome and cleave double stranded DNA, thus interrupting the expression of any given target gene
TALENs are described as artificial systems that can be designed and constructed relatively quickly to bind practically anywhere in the genome and cleave double-stranded DNA, thereby interrupting expression of a target gene.
Transcription activator-like effector nucleases (TALENs) are artificial systems that can be designed and constructed relatively quickly to bind practically anywhere in the genome and cleave double stranded DNA, thus interrupting the expression of any given target gene
TALENs are described as artificial systems that can be designed and constructed relatively quickly to bind practically anywhere in the genome and cleave double-stranded DNA, thereby interrupting expression of a target gene.
Transcription activator-like effector nucleases (TALENs) are artificial systems that can be designed and constructed relatively quickly to bind practically anywhere in the genome and cleave double stranded DNA, thus interrupting the expression of any given target gene
The abstract states that CRISPR/Cas9 has effectiveness at cleaving genomic DNA in mammalian cells in vitro and in vivo, exhibits specificity, and is relatively easy to construct in targeted forms.
Its effectiveness at cleaving genomic DNA in mammalian cells in vitro and in vivo [2, 3], the specificity that this system exhibits [4, 5] and the relative ease with which targeted systems can be constructed
This review focuses on four common gene-therapy-related modalities used to alter gene expression: siRNAs, TALENs, ZFNs, and CRISPR/Cas9.
Within this review we focus on 4 of the more common forms of gene therapy utilised to alter gene expression; siRNAs, TALENs, ZFNs and CRISPR/Cas9.
This review focuses on four common gene-therapy-related modalities used to alter gene expression: siRNAs, TALENs, ZFNs, and CRISPR/Cas9.
Within this review we focus on 4 of the more common forms of gene therapy utilised to alter gene expression; siRNAs, TALENs, ZFNs and CRISPR/Cas9.
This review focuses on four common gene-therapy-related modalities used to alter gene expression: siRNAs, TALENs, ZFNs, and CRISPR/Cas9.
Within this review we focus on 4 of the more common forms of gene therapy utilised to alter gene expression; siRNAs, TALENs, ZFNs and CRISPR/Cas9.
This review focuses on four common gene-therapy-related modalities used to alter gene expression: siRNAs, TALENs, ZFNs, and CRISPR/Cas9.
Within this review we focus on 4 of the more common forms of gene therapy utilised to alter gene expression; siRNAs, TALENs, ZFNs and CRISPR/Cas9.
This review focuses on four common gene-therapy-related modalities used to alter gene expression: siRNAs, TALENs, ZFNs, and CRISPR/Cas9.
Within this review we focus on 4 of the more common forms of gene therapy utilised to alter gene expression; siRNAs, TALENs, ZFNs and CRISPR/Cas9.
This review focuses on four common gene-therapy-related modalities used to alter gene expression: siRNAs, TALENs, ZFNs, and CRISPR/Cas9.
Within this review we focus on 4 of the more common forms of gene therapy utilised to alter gene expression; siRNAs, TALENs, ZFNs and CRISPR/Cas9.
This review focuses on four common gene-therapy-related modalities used to alter gene expression: siRNAs, TALENs, ZFNs, and CRISPR/Cas9.
Within this review we focus on 4 of the more common forms of gene therapy utilised to alter gene expression; siRNAs, TALENs, ZFNs and CRISPR/Cas9.
Approval Evidence
6 sources16 linked approval claimsfirst-pass slugs sirna, small-interfering-rna
Advances in high-throughput sequencing, structural biology, and delivery technologies have accelerated the development of diverse RNA therapeutics, including small interfering RNA (siRNA).
Source:
siRNA is a double-stranded RNA molecule that has the potential to inhibit gene expression by degrading target mRNA.
Source:
This review examines various gene therapy strategies, including ASOs, small interfering RNA (siRNAs), optogenetics, chemogenetics, and CRISPR...
Source:
Suppression of NF-κβ can be achieved through many modalities including anti-sense oligonucleotides (ASOs), siRNA (small interfering RNA), factors regulating NF-κβ, and microbes.
Source:
small interfering RNAs and microRNAs (miRNAs)
Source:
Within this review we focus on 4 of the more common forms of gene therapy utilised to alter gene expression; siRNAs, TALENs, ZFNs and CRISPR/Cas9. Short-interfering RNAs (siRNAs) are one method of transiently down regulating the expression of any target gene through the exploitation of the RNA interference pathway
Source:
application scopesupports
RNA-based strategies are applied to gene silencing, editing, protein replacement, immune activation, and targeted drug delivery.
Source:
disease emphasissupports
ASOs and siRNAs receive special emphasis for neurological, metabolic, and infectious diseases.
Source:
field shiftsupports
RNA-targeted therapy is shifting molecular medicine from a protein-centric view toward an RNA-regulatory network paradigm.
Source:
modality coveragesupports
Diverse RNA therapeutics include ASOs, siRNA, miRNA modulators, mRNA therapeutics, aptamers, shRNA, and CRISPR/Cas-guided single-guide RNAs.
Source:
translational barriersupports
Common challenges for RNA therapeutics include in vivo stability, delivery efficiency, and immune activation.
Source:
design requirementsupports
Effective siRNA gene knockdown requires precise sequence design to maximize efficacy and minimize off-target effects.
Source:
engineering considerationsupports
In vivo siRNA applications are challenged by delivery, biodistribution, and immunotoxicity, and these issues require specific mitigation strategies.
Source:
mechanismsupports
siRNA can inhibit gene expression by degrading target mRNA.
Source:
mechanistic design principlesupports
Approaches that prevent off-target RNAi and promote incorporation of the intended guide or antisense strand into RISC are emphasized for effective siRNA knockdown.
Source:
modification effectsupports
Chemical modifications to the ribose sugar and phosphodiester bonds affect siRNA stability, activity, and interaction with the RISC complex.
Source:
scope of reviewsupports
The review covers ASOs, siRNAs, optogenetics, chemogenetics, CRISPR, and their delivery methods targeting primary sensory neurons and non-neuronal cells including glia and chondrocytes.
Source:
translational landscapesupports
Although gene therapy-based clinical trials have increased, trials focused on pain as the primary outcome remain uncommon.
Source:
review scope summarysupports
The review states that non-protein-coding RNAs are biologically relevant regulators of critical plant processes.
The biological relevance of non-protein coding RNAs in the regulation of critical plant processes has been firmly established in recent years.
Source:
therapeutic strategysupports
Suppression of NF-κβ can be achieved through modalities including ASOs, siRNA, factors regulating NF-κβ, and microbes.
Source:
mechanism summarysupports
siRNAs are described as a method for transient downregulation of target gene expression through the RNA interference pathway.
Short-interfering RNAs (siRNAs) are one method of transiently down regulating the expression of any target gene through the exploitation of the RNA interference pathway
Source:
review scope summarysupports
This review focuses on four common gene-therapy-related modalities used to alter gene expression: siRNAs, TALENs, ZFNs, and CRISPR/Cas9.
Within this review we focus on 4 of the more common forms of gene therapy utilised to alter gene expression; siRNAs, TALENs, ZFNs and CRISPR/Cas9.
Source:
Comparisons
Source-stated alternatives
The review compares siRNA with ASOs, miRNA modulators, mRNA therapeutics, aptamers, shRNA, and CRISPR/Cas-guided single-guide RNAs.; The abstract does not name direct alternative gene-silencing modalities, but it contrasts better versus poorly designed siRNA sequences and discusses design strategies to improve performance.; Alternatives named in the abstract include ASOs, RNAi, CRISPR, optogenetics, chemogenetics, and virus-based delivery systems.; The abstract contrasts siRNA with ASOs, factors regulating NF-κβ, and microbes.
Source:
The review compares siRNA with ASOs, miRNA modulators, mRNA therapeutics, aptamers, shRNA, and CRISPR/Cas-guided single-guide RNAs.
Source:
The abstract does not name direct alternative gene-silencing modalities, but it contrasts better versus poorly designed siRNA sequences and discusses design strategies to improve performance.
Source:
Alternatives named in the abstract include ASOs, RNAi, CRISPR, optogenetics, chemogenetics, and virus-based delivery systems.
Source:
The abstract contrasts siRNA with ASOs, factors regulating NF-κβ, and microbes.
Source-backed strengths
The supplied evidence states that siRNA can transiently downregulate the expression of any target gene through the RNA interference pathway. This positions siRNA as a flexible knockdown modality for gene-expression control.
Source:
Its effectiveness at cleaving genomic DNA in mammalian cells in vitro and in vivo [2, 3], the specificity that this system exhibits [4, 5] and the relative ease with which targeted systems can be constructed
Compared with antisense oligonucleotide
The review compares siRNA with ASOs, miRNA modulators, mRNA therapeutics, aptamers, shRNA, and CRISPR/Cas-guided single-guide RNAs.; Alternatives named in the abstract include ASOs, RNAi, CRISPR, optogenetics, chemogenetics, and virus-based delivery systems.; The abstract contrasts siRNA with ASOs, factors regulating NF-κβ, and microbes.
Shared frame: source-stated alternative in extracted literature
Strengths here: highlighted as a major RNA therapeutic modality; given special emphasis for neurological, metabolic, and infectious diseases; versatile across research and therapeutic applications.
Relative tradeoffs: broader clinical application is limited by translational barriers; common challenges include in vivo stability, delivery efficiency, and immune activation; requires precise sequence design for effective knockdown.
Source:
The review compares siRNA with ASOs, miRNA modulators, mRNA therapeutics, aptamers, shRNA, and CRISPR/Cas-guided single-guide RNAs.
Source:
Alternatives named in the abstract include ASOs, RNAi, CRISPR, optogenetics, chemogenetics, and virus-based delivery systems.
Source:
The abstract contrasts siRNA with ASOs, factors regulating NF-κβ, and microbes.
Compared with anti-sense oligonucleotides
The review compares siRNA with ASOs, miRNA modulators, mRNA therapeutics, aptamers, shRNA, and CRISPR/Cas-guided single-guide RNAs.; Alternatives named in the abstract include ASOs, RNAi, CRISPR, optogenetics, chemogenetics, and virus-based delivery systems.; The abstract contrasts siRNA with ASOs, factors regulating NF-κβ, and microbes.
Shared frame: source-stated alternative in extracted literature
Strengths here: highlighted as a major RNA therapeutic modality; given special emphasis for neurological, metabolic, and infectious diseases; versatile across research and therapeutic applications.
Relative tradeoffs: broader clinical application is limited by translational barriers; common challenges include in vivo stability, delivery efficiency, and immune activation; requires precise sequence design for effective knockdown.
Source:
The review compares siRNA with ASOs, miRNA modulators, mRNA therapeutics, aptamers, shRNA, and CRISPR/Cas-guided single-guide RNAs.
Source:
Alternatives named in the abstract include ASOs, RNAi, CRISPR, optogenetics, chemogenetics, and virus-based delivery systems.
Source:
The abstract contrasts siRNA with ASOs, factors regulating NF-κβ, and microbes.
Compared with antisense oligonucleotides
The review compares siRNA with ASOs, miRNA modulators, mRNA therapeutics, aptamers, shRNA, and CRISPR/Cas-guided single-guide RNAs.; Alternatives named in the abstract include ASOs, RNAi, CRISPR, optogenetics, chemogenetics, and virus-based delivery systems.; The abstract contrasts siRNA with ASOs, factors regulating NF-κβ, and microbes.
Shared frame: source-stated alternative in extracted literature
Strengths here: highlighted as a major RNA therapeutic modality; given special emphasis for neurological, metabolic, and infectious diseases; versatile across research and therapeutic applications.
Relative tradeoffs: broader clinical application is limited by translational barriers; common challenges include in vivo stability, delivery efficiency, and immune activation; requires precise sequence design for effective knockdown.
Source:
The review compares siRNA with ASOs, miRNA modulators, mRNA therapeutics, aptamers, shRNA, and CRISPR/Cas-guided single-guide RNAs.
Source:
Alternatives named in the abstract include ASOs, RNAi, CRISPR, optogenetics, chemogenetics, and virus-based delivery systems.
Source:
The abstract contrasts siRNA with ASOs, factors regulating NF-κβ, and microbes.
Compared with aptazyme-embedded guide RNAs
The review compares siRNA with ASOs, miRNA modulators, mRNA therapeutics, aptamers, shRNA, and CRISPR/Cas-guided single-guide RNAs.
Shared frame: source-stated alternative in extracted literature
Strengths here: highlighted as a major RNA therapeutic modality; given special emphasis for neurological, metabolic, and infectious diseases; versatile across research and therapeutic applications.
Relative tradeoffs: broader clinical application is limited by translational barriers; common challenges include in vivo stability, delivery efficiency, and immune activation; requires precise sequence design for effective knockdown.
Source:
The review compares siRNA with ASOs, miRNA modulators, mRNA therapeutics, aptamers, shRNA, and CRISPR/Cas-guided single-guide RNAs.
Compared with chemogenetics
Alternatives named in the abstract include ASOs, RNAi, CRISPR, optogenetics, chemogenetics, and virus-based delivery systems.
Shared frame: source-stated alternative in extracted literature
Strengths here: highlighted as a major RNA therapeutic modality; given special emphasis for neurological, metabolic, and infectious diseases; versatile across research and therapeutic applications.
Relative tradeoffs: broader clinical application is limited by translational barriers; common challenges include in vivo stability, delivery efficiency, and immune activation; requires precise sequence design for effective knockdown.
Source:
Alternatives named in the abstract include ASOs, RNAi, CRISPR, optogenetics, chemogenetics, and virus-based delivery systems.
Compared with CRISPR/Cas9
The review compares siRNA with ASOs, miRNA modulators, mRNA therapeutics, aptamers, shRNA, and CRISPR/Cas-guided single-guide RNAs.; Alternatives named in the abstract include ASOs, RNAi, CRISPR, optogenetics, chemogenetics, and virus-based delivery systems.
Shared frame: source-stated alternative in extracted literature
Strengths here: highlighted as a major RNA therapeutic modality; given special emphasis for neurological, metabolic, and infectious diseases; versatile across research and therapeutic applications.
Relative tradeoffs: broader clinical application is limited by translational barriers; common challenges include in vivo stability, delivery efficiency, and immune activation; requires precise sequence design for effective knockdown.
Source:
The review compares siRNA with ASOs, miRNA modulators, mRNA therapeutics, aptamers, shRNA, and CRISPR/Cas-guided single-guide RNAs.
Source:
Alternatives named in the abstract include ASOs, RNAi, CRISPR, optogenetics, chemogenetics, and virus-based delivery systems.
Compared with CRISPR/Cas9 system
The review compares siRNA with ASOs, miRNA modulators, mRNA therapeutics, aptamers, shRNA, and CRISPR/Cas-guided single-guide RNAs.; Alternatives named in the abstract include ASOs, RNAi, CRISPR, optogenetics, chemogenetics, and virus-based delivery systems.
Shared frame: source-stated alternative in extracted literature
Strengths here: highlighted as a major RNA therapeutic modality; given special emphasis for neurological, metabolic, and infectious diseases; versatile across research and therapeutic applications.
Relative tradeoffs: broader clinical application is limited by translational barriers; common challenges include in vivo stability, delivery efficiency, and immune activation; requires precise sequence design for effective knockdown.
Source:
The review compares siRNA with ASOs, miRNA modulators, mRNA therapeutics, aptamers, shRNA, and CRISPR/Cas-guided single-guide RNAs.
Source:
Alternatives named in the abstract include ASOs, RNAi, CRISPR, optogenetics, chemogenetics, and virus-based delivery systems.
Compared with guide RNA
The review compares siRNA with ASOs, miRNA modulators, mRNA therapeutics, aptamers, shRNA, and CRISPR/Cas-guided single-guide RNAs.
Shared frame: source-stated alternative in extracted literature
Strengths here: highlighted as a major RNA therapeutic modality; given special emphasis for neurological, metabolic, and infectious diseases; versatile across research and therapeutic applications.
Relative tradeoffs: broader clinical application is limited by translational barriers; common challenges include in vivo stability, delivery efficiency, and immune activation; requires precise sequence design for effective knockdown.
Source:
The review compares siRNA with ASOs, miRNA modulators, mRNA therapeutics, aptamers, shRNA, and CRISPR/Cas-guided single-guide RNAs.
Compared with microRNA
The review compares siRNA with ASOs, miRNA modulators, mRNA therapeutics, aptamers, shRNA, and CRISPR/Cas-guided single-guide RNAs.
Shared frame: source-stated alternative in extracted literature
Strengths here: highlighted as a major RNA therapeutic modality; given special emphasis for neurological, metabolic, and infectious diseases; versatile across research and therapeutic applications.
Relative tradeoffs: broader clinical application is limited by translational barriers; common challenges include in vivo stability, delivery efficiency, and immune activation; requires precise sequence design for effective knockdown.
Source:
The review compares siRNA with ASOs, miRNA modulators, mRNA therapeutics, aptamers, shRNA, and CRISPR/Cas-guided single-guide RNAs.
Compared with optogenetic functional interrogation
Alternatives named in the abstract include ASOs, RNAi, CRISPR, optogenetics, chemogenetics, and virus-based delivery systems.
Shared frame: source-stated alternative in extracted literature
Strengths here: highlighted as a major RNA therapeutic modality; given special emphasis for neurological, metabolic, and infectious diseases; versatile across research and therapeutic applications.
Relative tradeoffs: broader clinical application is limited by translational barriers; common challenges include in vivo stability, delivery efficiency, and immune activation; requires precise sequence design for effective knockdown.
Source:
Alternatives named in the abstract include ASOs, RNAi, CRISPR, optogenetics, chemogenetics, and virus-based delivery systems.
Compared with optogenetic membrane potential perturbation
Alternatives named in the abstract include ASOs, RNAi, CRISPR, optogenetics, chemogenetics, and virus-based delivery systems.
Shared frame: source-stated alternative in extracted literature
Strengths here: highlighted as a major RNA therapeutic modality; given special emphasis for neurological, metabolic, and infectious diseases; versatile across research and therapeutic applications.
Relative tradeoffs: broader clinical application is limited by translational barriers; common challenges include in vivo stability, delivery efficiency, and immune activation; requires precise sequence design for effective knockdown.
Source:
Alternatives named in the abstract include ASOs, RNAi, CRISPR, optogenetics, chemogenetics, and virus-based delivery systems.
Compared with sgRNA
The review compares siRNA with ASOs, miRNA modulators, mRNA therapeutics, aptamers, shRNA, and CRISPR/Cas-guided single-guide RNAs.
Shared frame: source-stated alternative in extracted literature
Strengths here: highlighted as a major RNA therapeutic modality; given special emphasis for neurological, metabolic, and infectious diseases; versatile across research and therapeutic applications.
Relative tradeoffs: broader clinical application is limited by translational barriers; common challenges include in vivo stability, delivery efficiency, and immune activation; requires precise sequence design for effective knockdown.
Source:
The review compares siRNA with ASOs, miRNA modulators, mRNA therapeutics, aptamers, shRNA, and CRISPR/Cas-guided single-guide RNAs.
Compared with synthetically engineered guide RNA
The review compares siRNA with ASOs, miRNA modulators, mRNA therapeutics, aptamers, shRNA, and CRISPR/Cas-guided single-guide RNAs.
Shared frame: source-stated alternative in extracted literature
Strengths here: highlighted as a major RNA therapeutic modality; given special emphasis for neurological, metabolic, and infectious diseases; versatile across research and therapeutic applications.
Relative tradeoffs: broader clinical application is limited by translational barriers; common challenges include in vivo stability, delivery efficiency, and immune activation; requires precise sequence design for effective knockdown.
Source:
The review compares siRNA with ASOs, miRNA modulators, mRNA therapeutics, aptamers, shRNA, and CRISPR/Cas-guided single-guide RNAs.
Ranked Citations
- 1.
- 2.
- 3.
- 4.
- 5.